TABLE 1 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Comorbidities can have major implications for cancer care. They might impact the timing of cancer diagnosis, compromise optimal care, affect treatment outcomes and increase...
